TBPH
Theravance Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · KY
$17.02
−0.12%Next report
Analyst consensus
- Next report date
- Nov 10, 2026
- EPS estimate
- $0.24
- Revenue estimate
- $22.0M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.11
- EPS estimate
- $0.07
- Revenue actual
- $20.7M
- Revenue estimate
- $22.5M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -184.7%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Hold
- Price target
- $17
- PT range
- $17 – $17
- Analysts
- 3
0 Buy3 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | $0.07 | -$0.11 | Miss -251.72% | $20.7M |
| May 7, 2026 | $0.03 | -$0.10 | Miss -443.57% | $17.7M |
| Mar 19, 2026 | $0.44 | $0.06 | Miss -86.36% | $45.9M |
| Aug 12, 2025 | -$0.14 | -$0.08 | Beat 42.86% | $26.2M |
| May 8, 2025 | -$0.11 | -$0.17 | Miss -54.55% | $15.4M |
| Feb 26, 2025 | -$0.05 | -$0.05 | In line | $18.8M |
| Feb 27, 2023 | -$0.20 | -$0.21 | Miss -5.00% | $14.6M |
| Aug 4, 2022 | -$0.06 | -$0.04 | Beat 33.33% | $11.1M |
| May 5, 2022 | -$0.12 | -$0.24 | Miss -100.00% | $13.2M |
| Feb 23, 2022 | -$0.30 | -$0.43 | Miss -43.33% | $14.9M |
| Nov 3, 2021 | -$0.60 | -$0.48 | Beat 20.00% | $13.2M |
| Aug 3, 2021 | -$0.96 | -$0.80 | Beat 16.67% | $12.9M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 10, 2026